EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial

Marion J White, Isabelle Zaccaria, Florence Ennahdi-Elidrissi, Alessandro Putzu, Saoussen Dimassi, Stéphane Luise, John Diaper, Stéphanie Mulin, Aurélie D Baudat, Béatrice Gil-Wey, Nadia Elia, Bernhard Walder und 1 weitere

British Journal of Anaesthesia · 2024

DOI: 10.1016/j.bja.2024.05.020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Anaesthesia, 2024. Verfasst von Marion J White und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Anaesthesiology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva,…. Hauptthemen laut MEDLINE: Ivabradine, Feasibility Studies, Perioperative Care, Cardiovascular Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Geneva University Hospitals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Perioperative myocardial injury after noncardiac surgery is associated with postoperative mortality. Heart rate (HR) is an independent risk factor for perioperative myocardial injury. In this pilot trial we tested the feasibility of a randomised, placebo-controlled trial of personalised HR-targeted perioperative ivabradine. METHODS: This was a single-centre, randomised, placebo-controlled, double-blind, parallel group, feasibility pilot trial conducted at Geneva University Hospitals. We included patients ≥75 yr old or ≥45 yr old with cardiovascular risk factors planned for intermediate- or high-risk surgery. Patients were randomised to receive ivabradine (2.5, 5.0, or 7.5 mg) or placebo according to their HR, twice daily, from the morning of surgery until postoperative day 2. Primary outcomes were appropriate dosage and blinding success rates. RESULTS: Between October 2020 and January 2022, we randomised 78 patients (recruitment rate of 1.3 patients week-1). Some 439 of 444 study drug administrations were adequate (99% appropriate dosage rate). The blinding success rate was 100%. There were 137 (31%) administrations of Pill A (placebo in both groups for HR ≤70 beats min-1). Nine (11.5%) patients had a high-sensitive cardiac troponin T elevation ≥14 ng L-1 between any two measurements. The number of bradycardia episodes was eight in the placebo group and nine in the ivabradine group. CONCLUSIONS: This pilot study demonstrates the feasibility of, and provides guidance for, a future trial testing the efficacy of personalised perioperative ivabradine. Future studies should include patients at higher risk of cardiac complications. CLINICAL TRIAL REGISTRATION: NCT04436016.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvabradineFeasibility StudiesPerioperative CareCardiovascular AgentsHeart RateHumansPilot ProjectsDouble-Blind MethodMaleAgedFemaleMiddle AgedPostoperative ComplicationsAged, 80 and overPrecision MedicineDose-Response Relationship, DrugSurgical Procedures, Operative

Stichwörter der Autor:innen

feasibilityivabradineperioperative complicationperioperative myocardial injurypilot studytroponin

Substanzen

IvabradineCardiovascular Agents

Autor:innen und Institutionen

  • Division of Anaesthesiology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Division of Anaesthesiology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Anaesthesiology, Pharmacology, Intensive C…

Förderung

  • Geneva University Hospitals

Zitieren

APA

White, M. J., Zaccaria, I., Ennahdi-Elidrissi, F., Putzu, A., Dimassi, S., Luise, S., Diaper, J., Mulin, S., Baudat, A. D., Gil-Wey, B., Elia, N., Walder, B., & Bollen Pinto, B. (2024). Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2024.05.020

Vancouver

White MJ, Zaccaria I, Ennahdi-Elidrissi F, Putzu A, Dimassi S, Luise S, et al. Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial. British Journal of Anaesthesia. 2024. doi:10.1016/j.bja.2024.05.020

BibTeX
@article{White2024,
  author = {White, Marion J and Zaccaria, Isabelle and Ennahdi-Elidrissi, Florence and Putzu, Alessandro and Dimassi, Saoussen and Luise, Stéphane and Diaper, John and Mulin, Stéphanie and Baudat, Aurélie D and Gil-Wey, Béatrice and Elia, Nadia and Walder, Bernhard and Bollen Pinto, Bernardo},
  title = {Personalised perioperative dosing of ivabradine in noncardiac surgery: a single-centre, randomised, placebo-controlled, double-blind feasibility pilot trial},
  journal = {British Journal of Anaesthesia},
  year = {2024},
  doi = {10.1016/j.bja.2024.05.020}
}
Kostenlos starten →